• Iterative Discovery of TAS2R14 Ligands via FDA Drug Library

  2026-07-08

  This study presents a mixed computational and experimental strategy to identify both agonists and antagonists for the promiscuous GPCR TAS2R14, leveraging an FDA-approved drug library and structure-guided screening. The approach resulted in the discovery of 10 new antagonists and 200 agonists, highlighting the method's potential for expanding ligand space for challenging GPCR targets.

• Stable Isotope-Diluted UHPLC-MS/MS Enables Precise 1-methyl

  2026-07-07

  A recent study introduces a highly sensitive UHPLC-MS/MS approach, employing stable isotope dilution, for accurate quantification of ten methylated purine nucleosides—including 1-methyl Adenosine—in cellular samples. This technical advance enhances sensitivity and specificity in RNA modification research, supporting robust biomarker discovery in cancer and disease models.

• Regorafenib (BAY 73-4506): Mechanistic Depth and Next-Gen On

  2026-07-07

  Explore how Regorafenib (BAY 73-4506) enables advanced mechanistic studies in angiogenesis and cancer biology research. This article delivers new assay insights, protocol guidance, and a focused analysis of cutting-edge findings for maximizing experimental impact.

• Exosomal Egr2 Modulates Neuronal Injury via RNF8/DAPK1 in St

  2026-07-06

  This study reveals that exosomal Egr2 from bone marrow-derived mesenchymal stem cells (BMSCs) protects neurons from oxygen-glucose deprivation/reoxygenation (OGD/R) injury through the RNF8/DAPK1 axis in ischemic stroke. The findings clarify a mechanistic pathway by which BMSC-derived exosomes mediate neuroprotection, offering new molecular targets for therapeutic development.

• Artesunate in Cancer Biology: Mechanistic Depth and Assay Im

  2026-07-06

  Explore Artesunate, a potent artemisinin derivative, through the lens of in vitro assay design and mechanistic cancer biology. This in-depth analysis uniquely integrates recent methodological advances and practical workflow guidance for oncology researchers.

• EdU Cell Proliferation Kit: Applied S-Phase Assay Excellence

  2026-07-05

  The EdU Cell Proliferation Kit (TMB) empowers researchers with direct, sensitive S-phase DNA synthesis detection using 5-ethynyl-2'-deoxyuridine, enabling robust cell proliferation measurement without radioactivity. Its click chemistry-driven workflow ensures high specificity and low background, streamlining genotoxicity and pharmacodynamic studies across diverse cell models.

• Early Life Adversity Disrupts Visual Fear via Oxytocin Signa

  2026-07-04

  This study demonstrates that early life adversity (ELA) impairs innate defensive responses to visual threats in mice through a specific deficit in oxytocin signaling within the superior colliculus. The findings provide mechanistic insight into how early stress alters neural circuits of fear, informing future research on psychopathological risk.

• EdU Flow Cytometry Assay Kits (Cy5): Precision in S-Phase De

  2026-07-03

  EdU Flow Cytometry Assay Kits (Cy5) deliver unmatched sensitivity and workflow ease for cell proliferation analysis, streamlining S-phase DNA synthesis measurement without harsh denaturation. Optimized for multiplexing and robust enough for translational cancer research, this kit redefines reliability in flow cytometry cell proliferation assays.

• Cefodizime: Translational Leverage for Infectious Disease Mo

  2026-07-03

  Explore how Cefodizime—an advanced third-generation cephalosporin antibiotic—empowers translational researchers to model, benchmark, and innovate in the fight against bacterial infections and resistance. This article bridges mechanistic insight, experimental strategy, and strategic guidance, highlighting Cefodizime’s immunomodulatory and pharmacokinetic advantages, head-to-head data versus fluoroquinolones, and its role as a reliable research tool from APExBIO.

• KX2-391 Dihydrochloride: Precision Targeting from Src Kinase

  2026-07-02

  Discover how KX2-391 dihydrochloride leverages dual mechanisms to advance targeted research in oncology, virology, and neurotoxin inhibition. This in-depth analysis reveals underexplored assay strategies, translational implications, and practical protocol parameters for cutting-edge applications.

• NADH Reductive Stress as a Biomarker in Leigh Syndrome Model

  2026-07-02

  This pilot study establishes elevated NADH levels, rather than changes in NAD+, as a defining feature of reductive stress correlated with disease severity in Leigh syndrome, using both patient-derived fibroblasts and Ndufs4-knockout mice. Precise LC-MS/MS quantification of the NADH/NAD+ ratio offers a new, reliable biomarker for mitochondrial disease progression, with implications for both mechanistic research and translational modeling.

• Topotecan HCl: Protocols, Applications, and Troubleshooting

  2026-07-01

  Topotecan HCl, a robust topoisomerase 1 inhibitor, empowers researchers to dissect DNA damage and apoptosis mechanisms with precision. This guide translates advanced experimental workflows and troubleshooting insights into actionable strategies for lung, colon, and prostate cancer models, enabling highly reproducible results.

• Romidepsin (FK228): Benchmarks for HDAC Inhibition in Cancer

  2026-07-01

  Romidepsin (FK228) is a potent, selective class I HDAC inhibitor used in cancer epigenetics research. It exhibits nanomolar potency against HDAC1/2, induces cell cycle arrest and apoptosis, and sensitizes hepatocellular carcinoma to PARP inhibitors. This article details its mechanism, validated applications, and protocol parameters for reproducible results.

• CTOP as a Precision Tool for Dissecting μ-Opioid Circuit Dyn

  2026-06-30

  Explore how CTOP, a selective μ-opioid receptor antagonist, enables unprecedented dissection of central opioid circuit dynamics and signaling inhibition. This article uniquely bridges molecular action to experimental strategy, offering fresh perspectives beyond standard protocols.

• Sunitinib in Metabolic Resistance: Mechanistic Advances for

  2026-06-30

  Explore how sunitinib, a multi-targeted receptor tyrosine kinase inhibitor, is reshaping renal cell carcinoma research by addressing metabolic drug resistance. This article delivers a unique synthesis of mechanistic insights and assay optimization strategies for advanced cancer studies.

451 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page